Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Breast cancer, early stage

4140 - Prognostic impact of Recurrence Score (RS), grade/Ki67 central pathological review, and anthracycline (A)-free vs. A-containing chemotherapy (CT) on distant and locoregional disease-free survival (DDFS/LRFS) in high clinical risk HER2- early breast cancer (EBC): WSG PlanB trial results


09 Sep 2017


Breast cancer, early stage


Cytotoxic Therapy;  Pathology/Molecular Biology;  Breast Cancer


Oleg Gluz


Annals of Oncology (2017) 28 (suppl_5): v605-v649. 10.1093/annonc/mdx440


O. Gluz1, U. Nitz1, M. Christgen2, W. Malter3, M. Clemens4, T. Reimer5, B. Nuding6, B. Aktas7, A. Stefek8, A. Ppllmanns9, F. Lorenz-Salehi10, C. Uleer11, P. Krabisch12, S. Kümmel13, C. Liedtke14, S. Shak15, R. Kates16, R. Wurstlein17, H.H. Kreipe2, N. Harbeck18

Author affiliations

  • 1 Breast Center Niederrhein, West German Study Group and Bethesda Clinics Mönchengladbach, 41061 - Mönchengladbach/DE
  • 2 Pathology, Medical School Hannover, Hannover/DE
  • 3 Department Of Gynecology And Obstetrics, University Clinics Cologne, Cologne/DE
  • 4 Oncology, Klinikum Mutterhaus der Borromäerinnen, 54290 - Trier/DE
  • 5 Gynecology, University Clinics Rostock, Rostock/DE
  • 6 Gynecology, Evangelisches Krankenhaus Bergisch Gladbach, 51465 - Bergisch Gladbach/DE
  • 7 Gynecology And Obstetrics, University Clinics Essen, Essen/DE
  • 8 Breast Center, Johanniter Clinics Stendal, Stendal/DE
  • 9 Gynecology And Obstetrics, Evangelical Hospital Oberhausen, Oberhausen/DE
  • 10 Gynecology, HSK Wiesbaden, Wiesbaden/DE
  • 11 --, Gynecological-oncology practice, Hildesheim/DE
  • 12 Gynecology And Obstetrics, City Hospital, Chemnitz/DE
  • 13 Breast Center, Kliniken Essen Mitte Evang. Huyssens-Stiftung, 45136 - Essen/DE
  • 14 Gynecology And Obstetrics, University SH.-Lübeck, 23538 - Lübeck/DE
  • 15 --, Genomic Health Inc, 94063 - Redwood City/US
  • 16 --, West German Study Group and Bethesda Clinics Mönchengladbach, 41061 - Mönchengladbach/DE
  • 17 Breast Center, Ludwig Maximilians University - Grosshadern, 81377 - Munich/DE
  • 18 Breast Center, University of Munich (LMU), Munich/DE


Abstract 4140


Optimal prognostic markers and survival impact of A-containing CT in HER2-, particularly HR+ EBC, are still a matter of debate.


WSG PlanB is the first prospective trial compared A-free 6xTC vs. standard 4xECà4xDoc in high-risk pN0 or pN+ HER2- EBC and RS > 11 in pN0-1 HR+/HER2- EBC. Primary endpoint was DFS. Secondary endpoints included DDFS/LRFS and overall survival (OS). Multivariable analysis included continuous RS, IHC4, ER, PR, Ki67 (centrally measured), local/central grade, age, nodal status, tumor size, treatment, surgery type.


From 2009 to 2011, PlanB enrolled 3198 pts. 2449 pts. were randomized. to 6xTC vs. 4xEC→4xDoc (n = 1222/1227). After 60 months median follow-up, similar 5y DFS of 90%, 5y DDFS of 94%/93% (TC/EC-Doc) and 5y OS of 95% were observed in both arms. Pts with RS 0-11 without CT (n = 348, 15.3%) had 5-year DFS of 94%, irrespective of nodal status. 5y DDFS was 97.8% in RS 0-11 pts (all and only ET-treated: pN0: 97.7%, pN1: 97.9%), 96.9% in RS12-25 and 89.7% in RS > 25 (p  25 vs. either RS 0-11 or RS 12-25). RS was the strongest independent predictor for DDFS (HR = 2.64; 95% CI: 1.67-4.17) in multivariable analysis (all and CT-treated); the model also included tumor size>2 cm, nodal status, local grade 3. 5y LRFS was 98.6% in RS 0-11, 99.3% in RS 12-25 and 98.0% in RS > 25 (p = 0.002 for RS > 25 vs. RS 12-25, p = 0.21 for RS > 25 vs. RS 0-11). In multivariable analysis Ki67 (HR = 3.62, 95% CI: 1.39-9.47), together with >pN2 and mastectomy (all and CT-treated) predicted LRFS.


We observed excellent 5y DDFS of 97.8% in clinically high/genomic low risk HER2- HR+ EBC pts treated by ET alone. TC and EC-Doc resulted in similar outcomes. High RS was predictive for poor DDFS and LRFS by univariable, and for DDFS by multivariable analysis; Ki67 was independently prognostic for LRFS. These first prospective data regarding the impact of RS on DDFS and LRFS in clinically intermediate/high-risk EBC underline the importance of using both clinicopathological and genomic markers for individualized therapy decisions.

Clinical trial identification

EUDRA-CT Number: 2008-004263-19

Legal entity responsible for the study

West German Study Group


Amgen; Sanofi-Aventis; Genomic Health


O. Gluz: Honoraria and/or travel support (GHI, Nanostring, Amgen, Roche). U. Nitz, S. Kümmel, C. Liedtke, S. Shak, H.H. Kreipe: Genomic Health. R. Wurstlein, N. Harbeck: Genomic Health, Agendia, Nanostring. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.